New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams' dynamism and local potential.
As a clinician involved for several years in cancer immunotherapy, in particular in leukemias, the creation of Marseille Immunopôle is a significant step forward. With the experience of the development of anti-KIR antibodies, we have shown the effectiveness of the Marseille’s research network in the field of immuno-oncology: from basic (CIML) to clinical research (IPC-SIRIC Marseille) through translational (CRCM) and industry research (Innate Pharma).
MI will enable the development of original and innovative approaches in cancer immunotherapy, based on these three pillars. New molecules currently under development at Innate Pharma and in new companies in Marseille reflect the teams’ dynamism and local potential.
The Pioneer Project draws on the collaborative environment of Marseille Immunopôle, which brings together clinicians, academics and industry players committed to the benefit of patients
The Explore covid-19 project was born from combining the forces of Marseille Immunopôle. It should lead us to better understand this new disease and improve the prognosis of our patients.
Cell- and tissue- based therapies and gene therapies hold great promise in the field of both immunotherapy and regenerative medicine.
AMU, IPC, AP-HM, Inserm
Today, the Covid-19 pandemic serves as an eye-opener, once again demonstrating the strength of the Marseille Immunopôle collective
Nassima CHOUAKI BENMANSOUR